Abeona Therapeutics Inc. (ABEO)

Market Cap	279.09M
Revenue (ttm)	400,000
Net Income (ttm)	82.35M
Shares Out	54.19M
EPS (ttm)	1.29
PE Ratio	4.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,552,393
Open	4.83
Previous Close	4.88
Day's Range	4.80 - 5.17
52-Week Range	3.93 - 7.54
Beta	1.12
Analysts	Strong Buy
Price Target	18.20 (+253.4%)
Earnings Date	Nov 12, 2025

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform progra...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 19, 1980
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: ABEO
• Website: https://www.abeonatherapeutics.com

Analyst Summary

According to 5 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price target is $18.2, which is an increase of 253.40% from the latest price.

Price Target

$18.2

(253.40% upside)

Analyst Consensus: Strong Buy